Financial Results Summary

Quarterly Performance (₹ in Million)

  • Revenue from Operations: ₹2,357 (Q2 FY26) vs ₹2,209 (Q2 FY25) - 7% growth
  • Other Income: ₹63 (Q2 FY26) vs ₹56 (Q2 FY25)
  • Total Income: ₹2,420 (Q2 FY26) vs ₹2,265 (Q2 FY25)
  • Profit Before Tax: ₹919 (Q2 FY26) vs ₹789 (Q2 FY25) - 16% growth
  • Tax Expense: ₹231 million (Current Tax: ₹234 million, Deferred Tax: ₹-3 million)
  • Net Profit: ₹688 million (Q2 FY26) vs ₹607 million (Q2 FY25)
  • Basic EPS: ₹29.87 (not annualized)

Half-Yearly Performance (₹ in Million)

  • Revenue from Operations: ₹4,649 (H1 FY26) vs ₹3,935 (H1 FY25) - 18% growth
  • Other Income: ₹119 (H1 FY26) vs ₹108 (H1 FY25)
  • Total Income: ₹4,768 (H1 FY26) vs ₹4,043 (H1 FY25)
  • Profit Before Tax: ₹1,826 (H1 FY26) vs ₹1,457 (H1 FY25) - 25% growth
  • Tax Expense: ₹460 million (Current Tax: ₹475 million, Deferred Tax: ₹-15 million)
  • Net Profit: ₹1,366 million (H1 FY26) vs ₹1,107 million (H1 FY25)
  • Basic EPS: ₹59.31 (not annualized)

Expense Breakdown (Q2 FY26, ₹ in Million)

  • Cost of Materials Consumed: ₹475
  • Purchases of stock in trade: ₹160
  • Changes in Inventories: ₹(72)
  • Employee benefits expense: ₹313
  • Finance costs: ₹4
  • Depreciation and amortisation: ₹33
  • Other expenses: ₹588
  • Total Expenses: ₹1,501

Balance Sheet Position (as of 30th June 2026, ₹ in Million)

  • Total Assets: ₹7,064
  • Non-current Assets: ₹430
  • Current Assets: ₹6,634 (including Inventories: ₹937, Trade Receivables: ₹498, Cash & Cash Equivalents: ₹4,902)
  • Equity: ₹3,479 (Share Capital: ₹230, Other Equity: ₹3,249)
  • Total Liabilities: ₹3,585
  • Non-current Liabilities: ₹314
  • Current Liabilities: ₹3,271

Cash Flow Statement (H1 FY26, ₹ in Million)

  • Cash from Operating Activities: ₹1,096
  • Cash from Investing Activities: ₹105
  • Cash from Financing Activities: ₹(47)
  • Net Increase in Cash: ₹1,154
  • Cash at Beginning: ₹3,748
  • Cash at End: ₹4,902

Key Operational Highlights

  • Domestic sales grew 12% year-on-year in Q2 FY26, aided by product relaunches
  • Export sales declined 9% year-on-year in Q2 FY26 due to high base effect
  • For H1 FY26, domestic sales grew 14% while export sales grew 27%
  • The company successfully relaunched Combiflam Suspension in June 2025 quarter, and Allegra Suspension and Depura Kids in September 2025 quarter following voluntary recalls in 2024

Regulatory and Accounting Notes

  • Financial results prepared in accordance with Indian Accounting Standards (Ind AS)
  • The company has a single business segment - 'Pharmaceutical Business'
  • No subsidiaries, associates or joint ventures as of June 30, 2026
  • Exceptional item of ₹66 million in Q2 FY25 pertained to reversal of demerger provisions
  • New Labour Codes effective November 21, 2025 resulted in ₹24 million past service cost recognized in FY25
  • Statutory auditors Price Waterhouse & Co issued unmodified review report

Board Meeting Details

  • Meeting held on Tuesday, 28th July 2026
  • Commenced at 4:00 p.m. and concluded at 6:00 p.m.
  • Results to be published in newspapers as per Regulation 47 of SEBI Listing Regulations
  • Results available on company website: https://www.sanofi.com/en/india/consumerhealthcare/investors/financial-results

Management Commentary

Himanshu Bakshi, Managing Director, stated: "Our performance this quarter reflects the disciplined execution on all fronts. Our targeted investments behind our brands and go-to-market capabilities are translating into profitable growth and market share gains in most of our brands, reinforcing our confidence in the strength of our strategy."